Richmond Research Institute

What Richmond Research Institute does

Richmond Research Institute (RRI) is an independent, not-for-profit academic research unit founded in 2014 through a partnership between Richmond Pharmacology Limited (RPL), a CRO established in 2001 by Dr Jörg Täubel, and St George's University of London. Headquartered at St George's Hospital in Tooting, London, RRI operates with 11-50 employees and is governed by a Scientific Steering Committee chaired by Professor John Camm (recipient of the ESC Gold Medal and Mackenzie Medal). Its mission centres on clinical trial safety optimisation across four research pillars: cardiac sciences and electrophysiology, drug-induced hepatic injury, ethnic and sex differences in drug response, and clinical trial design methodology. The institute conducts early-phase clinical studies, biomarker research, and precision medicine investigations, with outputs disseminated via over 250 peer-reviewed publications and presentations at premier conferences (AHA, AASLD, ESC, Safety Pharmacology Society).

The institute's technology stack comprises clinical research methodologies including ECG/QT-interval cardiac safety assessments, biomarker analytics, big data interrogation, and telehealth remote-monitoring systems. Notable capabilities include advanced ECG monitoring and QT/QTc analysis for drug cardiac safety evaluation (leveraging Dr Mendzelevski's foundational European CRO ECG laboratory), an AI-driven NAFLD prediction nomogram (AUROC 0.93 for steatosis), and a smart-scale-based telehealth platform for cardiac amyloidosis patients under the PATHWAY-RCT study. RRI participates in multi-test COVID-19 protocols (PCR, antibody, lateral flow, Virolens holographic imaging) and collaborates on first-in-human CRISPR-Cas9 gene editing trials with Intellia Therapeutics and Regeneron Pharmaceuticals.

RRI's commercial model is grant- and collaboration-driven rather than product-based. Funding flows from research grants, co-sponsored pharmaceutical studies, and academic partnership contributions. Sponsor relationships include Intellia Therapeutics, Regeneron Pharmaceuticals, and the National Amyloidosis Centre; academic partners span St George's University of London, Kings College London, Aalborg University, University of Copenhagen, Pompeu Fabra University, Toho University, and the Liverpool School of Tropical Medicine. RRI joined the FNIH Biomarkers Consortium in December 2023 to participate in pre-competitive biomarker development. Pricing is not publicly disclosed, consistent with its non-profit academic mandate and absence of commercial product sales.

Name

Richmond Research Institute

Legal name

Richmond Research Institute

Website

https://richmondresearchinstitute.org

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Richmond Research Institute is an independent, not-for-profit academic research unit in London dedicated to clinical trial safety optimisation, conducting early-phase studies across cardiac safety, hepatology, ethnic and sex differences, and clinical trial methodology for pharmaceutical sponsors and academic collaborators.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Medical Laboratories (621511), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro industry

PRIMARYHLACAOAI

Clinical Trial Analytics, Risk-Based Monitoring (RBM) & Quality Management

Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

SECONDARYEDAHAGAI

Biomedical Sciences & Medical Research Institutes (University-Based)

Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities

SECONDARYHLAFAMAL

Clinical Research & Trial Central Laboratories

Healthcare & Life Sciences/Healthcare Providers & Systems/Clinical Laboratories

SECONDARYEDAHAGAA

Academic Medical Centers & Teaching Hospitals (University-Affiliated)

Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities

Keywords

• Clinical trial safety
• Cardiac safety research
• Hepatology research
• Precision medicine studies
• Early phase clinical trials

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Grant Funding: Research institute funded through grants and academic funding partnerships
2. Collaborative Research: Partnership-based research with academic institutions, pharmaceutical companies, and healthcare organizations

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Richmond Research Institute is an independent, not-for-profit academic research unit dedicated to clinical trial safety optimisation. It conducts academic research across cardiac safety, hepatology, clinical trial methodology, and ethnic/sex differences in drug response, leveraging state-of-the-art clinical trial facilities at Richmond Pharmacology to generate peer-reviewed scientific findings and advance patient safety.

Product overview

Richmond Research Institute is an independent, not-for-profit academic research unit dedicated to clinical trial safety optimization. The organization operates as a unified research institute offering comprehensive clinical research services across multiple therapeutic focus areas including cardiac health, hepatology, clinical trial methodology, and precision medicine. The core offering consists of academic research programs focused on improving patient safety in clinical trials, supported by COVID-19 testing services and extensive publication of scientific findings in peer-reviewed journals.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Safety Optimization Research
• COVID-19 Testing Services
• Cardiac Health Research
• Hepatology Research
• PATHWAY-RCT Telehealth Monitoring Study
• NAFLD Prediction Tool

Quantifiable outcome

• QTc prolongation of 27ms observed with hyperglycemia combined with moxifloxacin in Type 1 diabetic patients
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• FNIH Biomarkers ConsortiumcoreStrategic or Co-development Partner · 19 December 2023Richmond Research Institute became a member of the Foundation for the National Institutes of Health's Biomarkers Consortium. The BC is a flagship initiative bridging basic research and drug development, operating in pre-competitive space with results released publicly. Spans therapeutic areas with contributions from academia, government, industry, and non-profits.
• Richmond Pharmacology Limited (RPL)coreStrategic or Co-development PartnerSister organization and key operational partner providing state-of-the-art clinical trial facilities. RPL's London Bridge facility is used for RRI's clinical studies. RPL acted quickly during COVID-19 to implement testing protocols and safety measures at the shared facility.
• St George's University of LondoncoreStrategic or Co-development PartnerPrimary academic host institution. RRI was established out of a partnership with St George's University of London and operates from their campus. Professor John Camm serves as Scientific Steering Committee Chair.
• Aalborg UniversityminorStrategic or Co-development PartnerAcademic research collaboration in clinical studies
• Kings College LondoncoreStrategic or Co-development PartnerActive research collaboration including joint research on ECG processing techniques and student supervision. James Rickard is Senior Visiting Lecturer at King's College London Institute of Pharmaceutics Science.
• Liverpool School of Tropical MedicineminorStrategic or Co-development PartnerAcademic research collaboration in clinical studies
• University of CopenhagenminorStrategic or Co-development PartnerAcademic research collaboration in clinical studies
• Pompeu Fabra University, BarcelonaminorStrategic or Co-development PartnerAcademic research collaboration in clinical studies
• Toho University, TokyominorStrategic or Co-development PartnerInternational academic research collaboration in clinical studies
• National Amyloidosis CentrecoreStrategic or Co-development PartnerClinical collaboration for PATHWAY-RCT telehealth study. Pioneering work during pandemic led to development of remote monitoring for ATTR amyloidosis patients to reduce hospital admissions.
• LEOSS (Lean European Open Survey on SARS-CoV-2)minorStrategic or Co-development PartnerInternational collaboration collecting COVID-19 positive patient data from patients worldwide. Aims to provide anonymous patient information registry for understanding clinical course and virus spread.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• PPD (Thermo Fisher Scientific): Global CRO and clinical research services organization now part of Thermo Fisher Scientific. Comparable through its clinical trial operations and cardiac safety service offerings, although PPD is many times the size of RRI.
• Medpace: Mid-size global CRO with full-service clinical development capabilities across multiple therapeutic areas. Relevant incumbent comparable through its clinical trial safety and Phase I service lines, though at materially greater scale.
• ICON plc: Global CRO offering comprehensive clinical research services including cardiac safety and clinical pharmacology. Comparable as a broad incumbent participant in the outsourced clinical trial safety market though with substantially larger scope and resources.
• IQVIA: One of the world's largest CROs offering broad clinical development, cardiac safety, and real-world evidence services. Overlaps with RRI's clinical trial safety work but operates at vastly greater scale and breadth across all therapeutic areas.
• Parexel: Global CRO providing clinical trial operations, regulatory consulting, and biopharmaceutical services. Comparable through its clinical trial safety and early-phase capabilities, though it operates as a much broader commercial sponsor-facing organization.

Direct peers

• Clario: Global clinical trial technology and cardiac safety organization providing ECG core lab and cardiac safety assessment services. Most directly comparable to RRI's cardiac safety / QT/QTc interval research focus and clinical trial methodology specialization.
• Richmond Pharmacology Limited: Sister organization and operational CRO co-founded by Dr Jörg Täubel in 2001 at St George's University Hospital. Provides the state-of-the-art clinical trial facilities that RRI uses to deliver its research, sharing leadership and a deep operational linkage with RRI.
• hVIVO: UK-listed clinical trial services company specializing in respiratory and infectious disease human challenge trials. Comparable in size and niche clinical trial focus, with similar UK academic roots and Phase I clinical delivery expertise.

Emerging players

• National Amyloidosis Centre: UK clinical research centre of excellence for amyloidosis based at the Royal Free Hospital, and a core PATHWAY-RCT partner of RRI. Comparable through its niche clinical research focus and translational research model supporting amyloidosis drug development.
• King's College London Clinical Trials Unit: Academic clinical trial research unit at one of RRI's core partner universities, conducting early-phase and methodology research. Directly comparable through its academic clinical trial research model and overlapping precision medicine research interests.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCzQSbBIPlChnxb9nPCcwt6Q
• Xx.com/richmondresear1
• LinkedInlinkedin.com/company/richmond-research-institute

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Richmond Research Institute